US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Maze Therapeutics

12.93

-0.4100-3.07%

Post-market: 12.90-0.0300-0.23%19:33 EDT

Volume:67.77K

Turnover:884.71K

Market Cap:566.30M

PE:38.54

High:13.60

Open:13.48

Low:12.78

Close:13.34

Loading ...

Overview Company News Filings

Maze Therapeutics, Inc. (MAZE) Gets a Buy from TD Cowen

Maze Therapeutics Q1 EPS $(1.15) Up From $(13.91) YoY

Maze Therapeutics Q1 2025: Reports $294.4M Cash Position, R&D Expenses Rise to $27.6M, No Sales or Net Income Data Provided

Maze Therapeutics Inc - Has $294.4 Mln Cash Runway Into H2 2027

THOMSON REUTERS

Maze Therapeutics Inc - Mze782 Phase 1 Trial Initial Data Expected Q3 2025

THOMSON REUTERS

Press Release: Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones

Maze Therapeutics Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

US Market's Undiscovered Gems Featuring ZJK Industrial And 2 More Small Caps

Simply Wall St.

Maze Therapeutics Price Target Maintained With a $19.00/Share by Guggenheim

TD Cowen Keeps Their Buy Rating on Maze Therapeutics, Inc. (MAZE)

Maze Therapeutics Q4 2024 GAAP EPS $(18.32) Vs. $(11.46) YoY, Raised $140M In Gross Proceeds In Upsized IPO In February 2025, Providing Expected Cash Runway Into H2 2027

Maze Therapeutics reports Q4 EPS ($18.32) vs ($11.46) last year

Maze Therapeutics Inc -Qtrly Shr Loss $18.32

THOMSON REUTERS

Maze Therapeutics Inc -Expects Current Cash & Cash Equivalents to Fund Operations Into Second Half of 2027

THOMSON REUTERS

Press Release: Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights

Maze Therapeutics receives positive ratings following recent IPO

BUZZ-Maze Therapeutics rises as brokerages initiate coverage post research quiet period

Maze Therapeutics Inc : TD Cowen Initiates Coverage With Buy Rating

THOMSON REUTERS

Maze Therapeutics Inc : Leerink Partners Initiates Coverage With Outperform Rating; Target Price $28

THOMSON REUTERS

TD Cowen Initiates Maze Therapeutics at Buy

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MAZE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MAZE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MAZE\",,,,,undefined,":{"symbol":"MAZE","market":"US","secType":"STK","nameCN":"Maze Therapeutics","latestPrice":12.93,"timestamp":1749240000000,"preClose":13.34,"halted":0,"volume":67773,"hourTrading":{"tag":"盘后","latestPrice":12.9,"preClose":12.93,"latestTime":"19:33 EDT","volume":15577,"amount":202194.06,"timestamp":1749252819977},"delay":0,"floatShares":16929527,"shares":43797166,"eps":0.33546,"marketStatus":"Market Closed","change":-0.41,"latestTime":"06-06 16:00:00 EDT","open":13.48,"high":13.6,"low":12.78,"amount":884714.570478,"amplitude":0.061469,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.33546,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"listingDate":1738299600000,"exchange":"NASDAQ","adjPreClose":13.34,"postHourTrading":{"tag":"盘后","latestPrice":12.9,"preClose":12.93,"latestTime":"19:33 EDT","volume":15577,"amount":202194.06,"timestamp":1749252819977},"volumeRatio":0.47257100928405693},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MAZE\",,,,,undefined,":{"symbol":"MAZE","floatShares":16929527,"roa":"11.44%","roe":"34.38%","lyrEps":1.421062,"volumeRatio":0.47257100928405693,"shares":43797166,"dividePrice":0,"high":13.6,"amplitude":0.061469,"preClose":13.34,"low":12.78,"week52Low":6.71,"pbRate":"1.94","psRate":"3.38","week52High":17,"institutionHeld":0,"latestPrice":12.93,"eps":0.33546,"divideRate":0,"volume":67773,"delay":0,"ttmEps":0.33546,"open":13.48,"prevYearClose":16,"prevWeekClose":10.01,"prevMonthClose":10.01,"prevQuarterClose":11.01,"fiveDayClose":10.01,"twentyDayClose":10.02,"sixtyDayClose":11.3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MAZE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2535814598","title":"Maze Therapeutics, Inc. (MAZE) Gets a Buy from TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2535814598","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535814598?lang=en_us&edition=fundamental","pubTime":"2025-05-15 06:45","pubTimestamp":1747262739,"startTime":"0","endTime":"0","summary":"In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Maze Therapeutics, Inc. (MAZE – Research Report). The company’...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maze-therapeutics-inc-maze-gets-a-buy-from-td-cowen?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maze-therapeutics-inc-maze-gets-a-buy-from-td-cowen?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4207","BK4566","TD","BK4585","MAZE","COWN","BK4007","BK4127"],"gpt_icon":0},{"id":"2535298007","title":"Maze Therapeutics Q1 EPS $(1.15) Up From $(13.91) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2535298007","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535298007?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:18","pubTimestamp":1747253896,"startTime":"0","endTime":"0","summary":"Maze Therapeutics (NASDAQ:MAZE) reported quarterly losses of $(1.15) per share. This is a 91.73 percent increase over losses of $(13.91) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45420733/maze-therapeutics-q1-eps-1-15-up-from-13-91-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"gpt_icon":0},{"id":"2535002461","title":"Maze Therapeutics Q1 2025: Reports $294.4M Cash Position, R&D Expenses Rise to $27.6M, No Sales or Net Income Data Provided","url":"https://stock-news.laohu8.com/highlight/detail?id=2535002461","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535002461?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:03","pubTimestamp":1747253013,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on May 14, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL9X3Kg0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","NDAQ"],"gpt_icon":0},{"id":"2535026150","title":"Maze Therapeutics Inc - Has $294.4 Mln Cash Runway Into H2 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2535026150","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535026150?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:01","pubTimestamp":1747252861,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nTUA7CPVKS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAZE","BK4007"],"gpt_icon":0},{"id":"2535002699","title":"Maze Therapeutics Inc - Mze782 Phase 1 Trial Initial Data Expected Q3 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2535002699","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535002699?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:01","pubTimestamp":1747252861,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nTUA7CPVKS:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAZE","BK4007"],"gpt_icon":0},{"id":"2535138002","title":"Press Release: Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2535138002","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535138002?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:01","pubTimestamp":1747252860,"startTime":"0","endTime":"0","summary":"MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease; Initial Data Expected in Q1 2026. MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in Q3 2025. Strong Balance Sheet with $294.4 Million in Cash and Cash Equivalents, Expected to Provide Cash Runway into H2 2027. SOUTH SAN FRANCISCO, Calif., May 14, 2025  -- Maze Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, today reported financial results for the first quarter ended March 31, 2025, and reiterated upcoming milestones.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE","FSGS"],"gpt_icon":0},{"id":"2535721056","title":"Maze Therapeutics Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2535721056","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535721056?lang=en_us&edition=fundamental","pubTime":"2025-05-13 19:30","pubTimestamp":1747135856,"startTime":"0","endTime":"0","summary":"Maze Therapeutics Inc., a clinical-stage biopharmaceutical company, will participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference on May 20, 2025. Jason Coloma, Ph.D., the CEO, will present a company overview and engage in one-on-one meetings. The presentation will be accessible on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on May 13, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nNDL8Qm6Qn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2095319765.USD","BK4112","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","NDAQ","BK4585","MAZE","LU2210150020.SGD","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU2210149790.SGD","BK4007"],"gpt_icon":0},{"id":"2528223847","title":"US Market's Undiscovered Gems Featuring ZJK Industrial And 2 More Small Caps","url":"https://stock-news.laohu8.com/highlight/detail?id=2528223847","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528223847?lang=en_us&edition=fundamental","pubTime":"2025-04-18 01:32","pubTimestamp":1744911170,"startTime":"0","endTime":"0","summary":"As the U.S. market grapples with volatility, marked by mixed performances in major indices and concerns over tariffs impacting economic growth, small-cap stocks have become a focal point for investors seeking potential opportunities beyond the turbulence affecting large caps. In this climate, identifying promising small-cap companies like ZJK Industrial involves looking for those with strong fundamentals and resilience to external pressures, making them potential undiscovered gems amid broader market uncertainties.Top 10 Undiscovered Gems With Strong Fundamentals In The United States. Click here to see the full list of 286 stocks from our US Undiscovered Gems With Strong Fundamentals screener.Get an in-depth perspective on ZJK Industrial's performance by reading our health report here.Overview: Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines for renal, cardiovascular, related metabolic diseases, and obesity ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/us-markets-undiscovered-gems-featuring-173250731.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ZJK","MAZE","SWBI","BK4161"],"gpt_icon":0},{"id":"2524415108","title":"Maze Therapeutics Price Target Maintained With a $19.00/Share by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2524415108","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524415108?lang=en_us&edition=fundamental","pubTime":"2025-04-02 23:54","pubTimestamp":1743609240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MAZE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 02, 2025 11:54 ET (15:54 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"gpt_icon":0},{"id":"2524148426","title":"TD Cowen Keeps Their Buy Rating on Maze Therapeutics, Inc. (MAZE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2524148426","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524148426?lang=en_us&edition=fundamental","pubTime":"2025-04-01 22:25","pubTimestamp":1743517520,"startTime":"0","endTime":"0","summary":"In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Maze Therapeutics, Inc. (MAZE – Research Report). The company’...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-keeps-their-buy-rating-on-maze-therapeutics-inc-maze?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-keeps-their-buy-rating-on-maze-therapeutics-inc-maze?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE","TD","COWN"],"gpt_icon":0},{"id":"2523948901","title":"Maze Therapeutics Q4 2024 GAAP EPS $(18.32) Vs. $(11.46) YoY, Raised $140M In Gross Proceeds In Upsized IPO In February 2025, Providing Expected Cash Runway Into H2 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2523948901","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523948901?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:39","pubTimestamp":1743421182,"startTime":"0","endTime":"0","summary":"Maze Therapeutics Q4 2024 GAAP EPS $(18.32) Vs. $(11.46) YoY, Raised $140M In Gross Proceeds In Upsized IPO In February 2025, Providing Expected Cash Runway Into H2 2027","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/25/03/44559054/maze-therapeutics-q4-2024-gaap-eps-18-32-vs-11-46-yoy-raised-140m-in-gross-proceeds-in-upsized-ip","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"gpt_icon":0},{"id":"2523594338","title":"Maze Therapeutics reports Q4 EPS ($18.32) vs ($11.46) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2523594338","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523594338?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:36","pubTimestamp":1743420986,"startTime":"0","endTime":"0","summary":"“Maze has reached a pivotal moment in our journey. On the heels of a successful IPO and with two ongoing clinical-stage programs – MZE829 for AKD a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-reports-q4-eps-18-32-vs-11-46-last-year?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-reports-q4-eps-18-32-vs-11-46-last-year?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE"],"gpt_icon":0},{"id":"2523948573","title":"Maze Therapeutics Inc -Qtrly Shr Loss $18.32","url":"https://stock-news.laohu8.com/highlight/detail?id=2523948573","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523948573?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:32","pubTimestamp":1743420769,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QC0B0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2523485509","title":"Maze Therapeutics Inc -Expects Current Cash & Cash Equivalents to Fund Operations Into Second Half of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2523485509","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523485509?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:32","pubTimestamp":1743420769,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QC0B0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAZE","BK4007"],"gpt_icon":0},{"id":"2523948396","title":"Press Release: Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2523948396","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523948396?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:30","pubTimestamp":1743420600,"startTime":"0","endTime":"0","summary":"MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease ; Initial Data Expected in Q1 2026. MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in H2 2025. Raised $140 Million in Gross Proceeds in Upsized IPO in February 2025, Providing Expected Cash Runway into H2 2027. SOUTH SAN FRANCISCO, Calif., March 31, 2025  -- Maze Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, cardiovascular and metabolic diseases, today reported financial results for the fourth quarter and year ended December 31, 2024, highlighted recent progress and reiterated upcoming milestones.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FSGS","BK4007","MAZE"],"gpt_icon":0},{"id":"2514704435","title":"Maze Therapeutics receives positive ratings following recent IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2514704435","media":"Investing.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514704435?lang=en_us&edition=fundamental","pubTime":"2025-02-26 05:11","pubTimestamp":1740517867,"startTime":"0","endTime":"0","summary":"Investing.com -- Maze Therapeutics Inc received bullish coverage from multiple analysts, with Guggenheim, JPMorgan, and TD Cowen initiating Buy or Overweight ratings on the company given its potential in genetically targeted therapies.Maze's lead drug candidate, MZE829, is an oral APOL1 inhibitor being developed for APOL1-mediated kidney disease. Analysts expect key Phase II HORIZON trial data in early 2026, with TD Cowen highlighting its potential to address over 1 million AKD patients and noting its potency advantage over Vertex's  inaxaplin. Guggenheim sees Maze as a compelling investment, given the estimated $10 billion to $15 billion market opportunity in APOL1-associated kidney disease.Beyond MZE829, Maze's pipeline includes MZE782, an SLC6A19 inhibitor targeting chronic kidney disease and phenylketonuria, with Phase I data expected in the second half of 2025. Analysts view it as a first-in-class therapy with significant commercial potential.JPMorgan, which set a $30 price target","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maze-therapeutics-receives-positive-ratings-211107907.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MAZE"],"gpt_icon":0},{"id":"2514968019","title":"BUZZ-Maze Therapeutics rises as brokerages initiate coverage post research quiet period","url":"https://stock-news.laohu8.com/highlight/detail?id=2514968019","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514968019?lang=en_us&edition=fundamental","pubTime":"2025-02-26 00:13","pubTimestamp":1740499987,"startTime":"0","endTime":"0","summary":"BUZZ-Maze Therapeutics rises as brokerages initiate coverage post research quiet period** Shares of Maze Therapeutics MAZE.O rise 4.8% to $11.34 ** Wall Street brokerages start coverage of the drug de","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nL3N3PG1OA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4207","BK4007","BK4588","SIVBQ","BK4585","MAZE","BK4589","BK4211"],"gpt_icon":0},{"id":"2514609960","title":"Maze Therapeutics Inc : TD Cowen Initiates Coverage With Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2514609960","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514609960?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:11","pubTimestamp":1740489109,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PG0OR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAZE","BK4007"],"gpt_icon":0},{"id":"2514098450","title":"Maze Therapeutics Inc : Leerink Partners Initiates Coverage With Outperform Rating; Target Price $28","url":"https://stock-news.laohu8.com/highlight/detail?id=2514098450","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514098450?lang=en_us&edition=fundamental","pubTime":"2025-02-25 20:03","pubTimestamp":1740485036,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PG0P8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2514067325","title":"TD Cowen Initiates Maze Therapeutics at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2514067325","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514067325?lang=en_us&edition=fundamental","pubTime":"2025-02-25 19:22","pubTimestamp":1740482522,"startTime":"0","endTime":"0","summary":"TD Cowen Initiates Maze Therapeutics at Buy","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","MAZE","COWN","TD","BK4207","BK4007","BK4127","BK4566"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":44,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MAZE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-14","symbol":"MAZE","fiscalQuarterEnding":"2025/03","expectedEps":-0.76,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-1.15},{"market":"US","date":"2025-03-31","symbol":"MAZE","fiscalQuarterEnding":"2024/12","expectedEps":-7.6,"name":null,"time":"","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"","actualEps":-18.32}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MAZE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MAZE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":4,"updateTime":1740542400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MAZE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MAZE","date":"2025-06-06","current":11.248853,"percent":0.931818,"low":6.347498,"twenty":7.782471,"median":8.89283,"eighty":9.769431,"high":12.681398,"avg":8.927521,"sd":1.379451,"marketCap":584254194},"quantilePoints":[{"date":"2025-01-31","current":12.681398,"twenty":12.46124,"median":12.543799,"eighty":12.626358,"marketCap":700431648},{"date":"2025-02-07","current":10.303636,"twenty":10.343265,"median":11.88881,"eighty":12.594654,"marketCap":569100714},{"date":"2025-02-14","current":8.972089,"twenty":9.94063,"median":10.40271,"eighty":12.302722,"marketCap":495555390},{"date":"2025-02-21","current":9.645788,"twenty":9.645788,"median":10.220414,"eighty":11.88881,"marketCap":532765822},{"date":"2025-02-28","current":10.081711,"twenty":9.495197,"median":10.081711,"eighty":10.604819,"marketCap":556843160},{"date":"2025-03-07","current":9.29705,"twenty":9.29705,"median":9.788453,"eighty":10.501783,"marketCap":513503951},{"date":"2025-03-14","current":8.956237,"twenty":8.972089,"median":9.582381,"eighty":10.303636,"marketCap":494679851},{"date":"2025-03-21","current":9.479345,"twenty":8.972089,"median":9.534826,"eighty":10.271932,"marketCap":523572656},{"date":"2025-03-28","current":8.93246,"twenty":8.956237,"median":9.495197,"eighty":10.168896,"marketCap":493366542},{"date":"2025-04-04","current":7.814885,"twenty":8.89283,"median":9.443679,"eighty":10.137192,"marketCap":408179251},{"date":"2025-04-11","current":6.372653,"twenty":8.695317,"median":9.384234,"eighty":10.081711,"marketCap":332850033},{"date":"2025-04-17","current":6.858987,"twenty":8.362362,"median":9.29705,"eighty":9.98026,"marketCap":358251746},{"date":"2025-04-25","current":6.456504,"twenty":7.783022,"median":9.224877,"eighty":9.897831,"marketCap":337229638},{"date":"2025-05-02","current":8.879789,"twenty":7.580103,"median":8.972089,"eighty":9.731387,"marketCap":463800243},{"date":"2025-05-09","current":8.40184,"twenty":7.63209,"median":8.956237,"eighty":9.655299,"marketCap":438836491},{"date":"2025-05-16","current":7.799992,"twenty":7.63958,"median":8.89283,"eighty":9.626766,"marketCap":405123785},{"date":"2025-05-23","current":8.575775,"twenty":7.65241,"median":8.850167,"eighty":9.590307,"marketCap":445417178},{"date":"2025-05-30","current":10.26226,"twenty":7.715941,"median":8.87535,"eighty":9.631522,"marketCap":533011510},{"date":"2025-06-06","current":11.248853,"twenty":7.782471,"median":8.89283,"eighty":9.769431,"marketCap":584254194}],"updateTime":1749393535974}}}